Akums Drugs & Pharmaceuticals Ltd
Akums Drugs & Pharmaceuticals Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
CDMO Business: - Expected mid-single-digit topline growth in FY26 due to continued soft API prices. - Rs. CDMO Business**: Targeting mid-single-digit top-line growth for FY26, a slight moderation due to soft API prices; margins expected around 14-15%.
From Akums Drugs & Pharmaceuticals Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- CDMO Business:
- - Expected mid-single-digit topline growth in FY26 due to continued soft API prices.
- - Rs. 300 crore annual revenue anticipated from the new EU CDMO contract starting April 2027, with full ramp-up possibly taking 2-3 years.
- - Five-year target of $100 million in exports, scaling up from the current $15 million in formulation exports.
- Domestic Branded Formulations:
- - Expected to track IPM growth, with subdued 3-4% growth in Q1 seen as a one-off.
- - Anticipated better performance in subsequent quarters, maintaining overall yearly guidance.
- International Branded Formulations:
- - High-teen growth expected for the full year despite weaker current quarter.
- API Business:
- - Continued focus on global expansion (Europe, Africa, LATAM) and improved API pricing.
- - Single-digit growth expected amidst pricing pressure domestically.
- Trade Generics:
- - Gradual rationalization expected; potential profitable units retained but no significant growth anticipated.
Profitability & Margins
See what Akums Drugs & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Jammu plant expansion: Capex to start towards the end of the current year, with completion and plant operational by March 2027.
- Current ongoing capex projects include expansion at Baddi plant and utilization ramp-up at Haridwar facility.
- Strategic inorganic investments focus on acquiring dosage form capabilities either within India or abroad to gain access to new markets and expand product portfolios.
- Consideration for acquisitions targeting companies with strong R&D, quality manufacturing, and global market access, aiming to launch new products quickly.
- The company is open to inorganic opportunities, supported by a healthy balance sheet and cash surplus of Rs. 1,518 crores.
- Overseas expansion through European market plays including dossier filings and registration via Akums Healthcare UK, aiming to build a larger portfolio with exclusive marketing authorizations over time.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Akums Drugs & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Akums Drugs & Pharmaceuticals has recently received a significant contract worth Rs. 300 crores linked to European markets.
- They have other ongoing contracts of smaller values in progress.
- Current export business run rate stands at Rs. 150 crores.
- Over a five-year horizon, the company targets around $100 million in exports from the CDMO and international branded formulation segments combined.
- The company is also working on expanding its European dossier approvals, including recently approved Rivaroxaban and upcoming dossiers like Dapagliflozin.
- There is no explicit mention of the total outstanding order book value, but the pipeline appears strong with new product filings and contract onboarding, targeting scalable growth over 3-5 years.
Akums Drugs & Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.2K Cr, net profit ₹81 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Akums Drugs & Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Sai Life Sciences Ltd (Q1 FY26)
Sai Life Sciences reported a strong Q1 FY'26 with revenue up 77% YoY, driven mainly by CDMO (113% growth) and CRO (38% growth). Key concall takeaways from Sai…
- Cipla Ltd (Q1 FY26)
One Africa business grew 11% YoY, with continued focus on expansion. Key concall takeaways from Cipla's Q1 FY26 earnings call — and how it ranks against sector…
- Anthem Biosciences Ltd (Q1 FY26)
Capacity utilization in custom synthesis is around 70%, with expansions ongoing, indicating potential for further revenue growth. Key concall takeaways from…
- Senores Pharmaceuticals Ltd (Q1 FY26)
. Key concall takeaways from Senores Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Akums Drugs & Pharmaceuticals Ltd Q1 FY26 results?
CDMO Business: - Expected mid-single-digit topline growth in FY26 due to continued soft API prices. - Rs. CDMO Business**: Targeting mid-single-digit top-line growth for FY26, a slight moderation due to soft API prices; margins expected around 14-15%.
What is Akums Drugs & Pharmaceuticals Ltd share price analysis?
Akums Drugs & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 37.5 with a market cap of ₹11,436 Cr. Investors should review the full earnings analysis for detailed insights.
Is Akums Drugs & Pharmaceuticals Ltd planning capital expenditure?
Jammu plant expansion: Capex to start towards the end of the current year, with completion and plant operational by March 2027.
Keep Akums Drugs & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.